A REVIEW OF POTASSIUM CHANNELS: THE POTENTIAL OF POTASSIUM CHANNELS AS A TREATMENT FOR EPILEPTIC DISEASES

Kapil Ishwar Deshmukh
Gajanan Maharaj College of Pharmacy Chh.Sambhajinagar
Kapildeshmukh671@gmail.com
Mr.Tejas More(M.Pharm), Department of pharmaceutical Chemistry, Gajanan Maharaj College of Pharmacy Chh.Sambhajinagar
Dr. Kavita Kulkarni (PhD.Mpharm), Department of Quality Assurance, Gajanan Maharaj College of Pharmacy Chh.Sambhajinagar.

Abstract

Potassium channels play a critical role in maintaining the electrical excitability of neurons by controlling the flow of potassium ions across the cell membrane, thereby regulating membrane potential and neuronal firing. Dysregulation of potassium channel function has been implicated in the pathophysiology of epilepsy, a neurological disorder characterized by recurrent seizures due to abnormal electrical activity in the brain. Emerging research highlights the therapeutic potential of modulating potassium channels to restore normal neuronal activity and prevent seizure generation. Various subtypes of potassium channels, such as voltage-gated (Kv), calcium-activated (Kca), and inwardly rectifying (Kir) channels, have been identified as key players in neuronal excitability. Pharmacological agents targeting these channels could offer new avenues for treating epilepsy, particularly in drugresistant cases. This review explores the role of potassium channels in epilepsy,

Potassium channels are essential regulators of neuronal excitability, influencing action potential repolarization and neurotransmitter release by modulating potassium ion flux across the membrane. Their dysfunction has been associated with various neurological disorders, particularly epilepsy, where abnormal electrical discharges result in recurrent seizures. Recent advances in neurobiology have emphasized the role of specific potassium channel subtypes, including voltage-gated potassium (Kv) channels, calcium-activated potassium (KCa) channels, and inwardly rectifying potassium (Kir) channels, in controlling seizure susceptibility. Mutations in genes encoding these channels, such as KCNQ2 and KCNT1, have been linked to rare genetic epilepsies, reinforcing the importance of potassium channels in epilepsy pathogenesis.

Introduction:

- Epilepsy is a common neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Despite the availability of antiepileptic drugs (AEDs), about one-third of patients continue to experience drug-resistant seizures, highlighting the need for novel therapeutic approaches. Potassium channels, which are integral in regulating neuronal excitability and maintaining the electrical stability of neurons, have emerged as promising targets for epilepsy treatment. These channels control the flow of potassium ions across the cell membrane, which in turn influences the membrane potential and the firing patterns of neurons.

- Potassium channels are classified into several types, including voltage-gated (Kv), calcium-activated (Kca), and inwardly rectifying (Kir) potassium channels. Each subtype plays a distinct role in maintaining neuronal excitability, repolarizing the membrane after action potentials, and preventing excessive firing. Dysfunction or mutations in potassium channel genes, such as KCNQ2, KCNA1, and KCNT1, have been linked to various forms of epilepsy, especially genetic epilepsies. These findings have sparked significant interest in exploring potassium channels as therapeutic targets.
- Pharmacological agents that modulate potassium channel activity offer a novel strategy for epilepsy management. By enhancing potassium conductance, these modulators could restore normal neuronal function, reducing hyperexcitability and preventing the initiation and spread of seizures. In recent years, compounds such as retigabine, which targets voltage-gated potassium channels, have shown promise in clinical settings. This introduction explores the potential of potassium channels as targets for treating epilepsy, outlining their role in neuronal function and the opportunities for developing innovative treatments based on potassium channel modulation.
- Calcium-activated potassium channels (Kca) are a large and diversified family of ion

Channels that transduce increases in intracellular Ca2+ ([Ca2+]i) into changes in membrane

Potential (hyperpolarization) that can then influence the duration and frequency of action

Potentials (Aps) in excitable cells (both pre- and postsynaptically) and thus exert an important

Influence on their functional properties. According to their single channel conductance, Ca2+

-

Activated K+

Channels can be divided into three subfamilies: small conductance (SK: 2-25 pS),

Intermediate conductance (IK: 25-100 pS) and large conductance (BK: 100–300 pS) subtypes;

Each subgroup also exhibit distinct pharmacological and biophysical characteristics1-4. In

Addition to their important regulatory roles, Ca2±activated K+

Channels also have an important

Potential as targets for novel therapeutic drugs in health and disease5-7. The BK channel (also

Referred to as BKCa, MaxiK, Slo1, Kca1.1) was the first of the Ca2±activated K+

Channels to

Be identified and is one of the most widely expressed channels in mammalian cells and tissues

Such as neurones, skeletal, smooth and cardiac muscles, exocrine cells, and the inner sensory
Hair cells of the cochlea8-10. BK channels are also unique in being activated both in response
To membrane depolarization and an increase of [Ca2+]i intracellular [Ca2+] (allosteric
Activation); in contrast, SK and IK channels are voltage-insensitive and are solely activated by
Increases in [Ca2+]i. Voltage and Ca2+ gating sites are separately coupled to the channel
Protein and trigger several conformational changes to activate the BK channel9
. Even though
Experimentally, membrane voltage and fluctuations in [Ca2+]i by themselves are able to alter
BK open channel probability, many observations have demonstrated that both membr

History:

The study of potassium channels has a long and rich history, beginning with the foundational discoveries in the early 20th century that established the role of ion channels in neuronal excitability. Early electrophysiological research in the 1940s and 1950s by Alan Hodgkin and Andrew Huxley laid the groundwork for understanding how ion channels, including potassium channels, contribute to the action potential in neurons. Their Nobel Prize-winning work on the squid giant axon demonstrated that potassium channels are crucial for repolarizing the neuronal membrane after an action potential, allowing neurons to return to their resting state and maintain proper electrical signaling.

By the 1970s and 1980s, advances in molecular biology

Types Epilepsy :

1. Focal Epilepsy (Partial Epilepsy)

Focal Aware Seizures (Simple Partial Seizures): The person remains fully aware but may experience unusual sensations, movements, or emotions.

Focal Impaired Awareness Seizures (Complex Partial Seizures): Awareness is impaired, and the person may appear confused or dazed, performing repetitive movements (automatisms).

Focal to Bilateral Tonic-Clonic Seizures: Seizures start in one area of the brain and spread to involve both sides, causing convulsions.

2. Generalized Epilepsy

Seizures involve both sides of the brain from the start.

Absence Seizures (Petit Mal Seizures): Characterized by brief, sudden lapses in awareness, often mistaken for daydreaming. Common in children.

Tonic-Clonic Seizures (Grand Mal Seizures): The most recognized seizure type, with loss of consciousness, stiffening of the body (tonic phase), and rhythmic jerking (clonic phase).

Myoclonic Seizures: Brief, shock-like jerks of a muscle or group of muscles.

Atonic Seizures: Sudden loss of muscle tone, causing the person to collapse or fall.

Tonic Seizures: Sudden stiffening of the muscles, often causing the person to fall backward.

Clonic Seizures: Rhythmic jerking movements, typically involving the arms, neck, or face.

3. Unknown Onset Epilepsy

When the onset of seizures is not clear or classified due to incomplete information.

4. Generalized and Focal Combined Epilepsy

This refers to epilepsy syndromes where both focal and generalized seizures occur, such as Lennox-Gastaut syndrome.

5. Epileptic Syndromes

These are epilepsy types associated with specific age groups, causes, or patterns of seizures:

Juvenile Myoclonic Epilepsy (JME): Typically starts in adolescence and involves myoclonic, tonic-clonic, or absence seizures.

Lennox-Gastaut Syndrome: A severe form of epilepsy that begins in childhood, featuring multiple seizure types and often intellectual disability.

Dravet Syndrome: A rare genetic epilepsy starting in infancy, characterized by frequent, prolonged seizures.

Benign Rolandic Epilepsy: Childhood epilepsy with infrequent seizures, often during sleep, that usually resolves by adolescence.

6. Reflex Epilepsy

Seizures are triggered by specific stimuli, such as flashing lights (photosensitive epilepsy), reading, or other sensory inputs.

Epilepsy types are often categorized based on the underlying cause, including:

Idiopathic Epilepsy: No identifiable cause.

Symptomatic Epilepsy: Linked to known structural or metabolic causes (e.g., brain injury, genetic conditions).

Cryptogenic Epilepsy: Presumed symptomatic, but the exact cause isn't clearly identified.

Treatment and prognosis vary depending on the type of epilepsy and its cause.

Pottasium channel in treatment of epileptic disease :



Potassium (K^+) channels play a critical role in the regulation of neuronal excitability, which is crucial in the context of epilepsy. Abnormal neuronal firing leads to seizures, and potassium channels help maintain the balance between excitation and inhibition in the brain by regulating the flow of potassium ions out of neurons. Here's how potassium channels are involved in epilepsy and its treatment:

1. Regulating Neuronal Excitability

Potassium channels help neurons return to their resting state after firing by allowing potassium ions to flow out of the cell. This repolarizes the neuron, making it less likely to fire again immediately. In epilepsy, where there is excessive, uncontrolled neuronal firing, the proper function of potassium channels is crucial in reducing this hyperexcitability.

2. Types of Potassium Channels Relevant to Epilepsy

Several types of potassium channels are relevant to epilepsy, each with a different role in controlling neuronal activity:

Voltage-Gated Potassium Channels (Kv): These channels open in response to changes in membrane potential. When neurons fire, Kv channels allow potassium to flow out, helping to stop the action potential and restore the resting membrane potential. Mutations in certain Kv channel genes (e.g., KCNQ2 and KCNQ3) can lead to epilepsy, especially in early-onset forms like benign familial neonatal epilepsy.

Inward-Rectifier Potassium Channels (Kir): These channels allow potassium to move into the neuron under certain conditions, helping to maintain resting membrane potential and reduce excessive firing. Two-Pore Domain Potassium Channels (K2P): These channels contribute to setting the resting membrane potential, and their dysfunction can also lead to abnormal neuronal firing.

3. Genetic Mutations in Potassium Channels and Epilepsy

Mutations in genes encoding potassium channels can cause epilepsy, particularly in syndromes like:

Benign Familial Neonatal Epilepsy (BFNE): Caused by mutations in KCNQ2 or KCNQ3 genes, leading to dysfunction in Kv7 potassium channels.

Early Infantile Epileptic Encephalopathy: Severe, early-onset epilepsy often related to mutations in potassium channel genes.

Dravet Syndrome: Although primarily linked to mutations in sodium channels (SCN1A), potassium channel dysfunction may also contribute to the disease.

4. Potassium Channel Openers in Epilepsy Treatment

Drugs that enhance the function of potassium channels (potassium channel openers) have been explored as potential treatments for epilepsy. By promoting the outward flow of potassium ions, these drugs reduce neuronal excitability and can prevent seizures. Examples include:

Retigabine (Ezogabine): This drug, approved for the treatment of partial seizures, enhances the activity of Kv7 (KCNQ) channels, stabilizing the membrane potential and reducing hyperexcitability in neurons. It helps prevent seizure activity by making neurons less likely to fire excessively. However, due to side effects, including retinal abnormalities, its use has become limited.

Other Experimental Compounds: Research continues on potassium channel modulators that target specific subtypes of channels involved in epilepsy. These drugs aim to balance the excitatory and inhibitory signals in the brain to prevent seizures without significant side effects.

5. Future Directions

Potassium channels are promising therapeutic targets for epilepsy, especially in genetically-defined cases of the disease. Ongoing research focuses on developing more selective potassium channel modulators that can provide seizure control with fewer side effects.

In summary, potassium channels play a pivotal role in managing neuronal excitability, and dysfunction in these channels can lead to epileptic seizures. Modulating their activity through potassium channel openers or other therapies represents

a promising strategy for treating epilepsy, especially in cases where genetic mutations in these channels are involved.

Drug work on pottasium channel for treatment of epileptic disease :

The primary drug that targets potassium channels for the treatment of epilepsy is Retigabine (also known as Ezogabine in the U.S.). Here's how it works and its role in epilepsy treatment:

Retigabine (Ezogabine)

Mechanism of Action: Retigabine works by activating KCNQ (Kv7) potassium channels, which are a subtype of voltage-gated potassium channels. By enhancing the flow of potassium ions out of the neuron, the drug stabilizes the neuronal membrane potential and reduces excessive neuronal firing, which helps prevent seizures.

Indication: It was approved for the treatment of partial-onset seizures in adults, particularly in cases that did not respond well to other treatments.

Effectiveness: Retigabine was shown to be effective in reducing seizure frequency by helping to control abnormal neuronal excitability, especially in focal (partial) epilepsies.

Limitations and Side Effects

Side Effects: Despite its effectiveness, Retigabine was associated with several side effects, including dizziness, drowsiness, urinary retention, and visual changes. One of the more serious side effects involved retinal abnormalities and potential vision loss, which led to limited use.

Withdrawal from Market: Due to safety concerns, especially regarding retinal pigmentation and the risk of vision loss, the drug was discontinued in many countries, including the U.S., in 2017. However, Retigabine paved the way for research into potassium channel modulators in epilepsy treatment.

Other Potential Drugs Targeting Potassium Channels

While Retigabine was the most well-known drug working on potassium channels, other potassium channel modulators are being researched or are in development as potential epilepsy treatments. These experimental drugs aim to target potassium channels with fewer side effects, offering hope for safer and more effective therapies.

Flupirtine: A drug with similar mechanisms to Retigabine, although not primarily used for epilepsy, but rather for pain relief. However, it also faced similar safety concerns.

Future research may yield more potassium channel modulators that could offer seizure control with improved safety profiles compared to Retigabine.

Phenytoin (Dilantin)

Carbamazepine (Tegretol) Lamotrigine (Lamictal) Oxcarbazepine (Trileptal) Lacosamide (Vimpat

Molecular structure of BK (big potassium) channels

BK (Big Potassium) channels, also known as large-conductance calcium-activated potassium channels (Kca1.1), are critical regulators of cellular excitability, controlling the flow of potassium ions across the cell membrane in response to both voltage changes and intracellular calcium levels. The molecular structure of BK channels is complex and highly specialized to fulfill its dual gating by voltage and calcium.

Structural Features of BK (big potassium) Channels:



1. Tetrameric Architecture: Like other potassium channels, BK channels are tetrameric, meaning they are composed of four identical subunits. Each subunit forms part of the ion-conducting pore. These subunits work together to create a central pore that selectively allows potassium ions to pass through.
2. S1-S6 Transmembrane Domains: Each subunit of the BK channel consists of seven membrane-spanning segments (S0-S6). The segments S1-S4 form the voltagesensing domain (VSD), while S5 and S6 contribute to the pore-forming region. The S4 segment is particularly important, as it contains positively charged residues that respond to changes in membrane voltage.
3. Pore-Forming Region: The pore is formed by the S5 and S6 transmembrane helices, with a selectivity filter that allows potassium ions to pass while excluding other ions. This region ensures the channel is selective for potassium ions.
4. Calcium-Binding Domains: BK channels have specialized regions that sense intracellular calcium, allowing calcium ions to bind and regulate the channel's activity. These include:

RCK1 and RCK2 (Regulator of Conductance for K+) domains: Located on the cytoplasmic C-terminal tail of each subunit, these domains play a critical role in calcium sensitivity. The RCK domains form a large cytosolic gating ring that binds calcium and modulates the channel's opening.

5. Gating Ring: The RCK1 and RCK2 domains form a gating ring structure that surrounds the intracellular face of the channel. The gating ring undergoes conformational changes upon calcium binding, which influences the opening of the channel by mechanically coupling with the pore.
6. S0 Segment: The S0 segment is an additional transmembrane domain unique to BK channels, located N-terminal to the VSD. This structure contributes to the channel's large size and its ability to integrate signals from both voltage and calcium.
7. Beta and Gamma Subunits: In addition to the main alpha subunits that form the pore, BK channels are modulated by auxiliary beta and gamma subunits. These subunits are membrane-bound proteins that can alter the channel's gating properties, calcium sensitivity, and

pharmacological responses. Different tissues may express different subunit combinations, leading to variability in BK channel function.

Functional Implication:

The combination of voltage sensing and calcium binding allows BK channels to integrate multiple physiological signals. When calcium levels rise or when the membrane depolarizes, the channel opens, allowing potassium ions to exit the cell. This hyperpolarizes the membrane and helps regulate muscle contraction, neurotransmitter release, and neuronal firing patterns, among other processes.

Summary of Structure:

Tetrameric formation of four identical subunits.

Voltage-sensing domain (S1-S4) for membrane potential detection.

Pore-forming region (S5-S6) with a potassium-selective filter.

RCK domains and gating ring for calcium binding and regulation.

Auxiliary beta and gamma subunits that modify the channel's activity.

This structure allows BK channels to finely regulate potassium ion flow in response to both electrical and chemical signals, making them essential for diverse physiological processes.

BK (big potassium) channels in the central nervous system: distribution and pharmacological Properties in the CNS:

BK channels (Kca1.1) are widely distributed throughout the central nervous system (CNS), playing a critical role in regulating neuronal excitability, synaptic transmission, and the overall electrical activity of neurons. Their localization and function vary depending on the brain region, cell type, and physiological demands.

1. **Neocortex:**

BK channels are found in both excitatory pyramidal neurons and inhibitory interneurons in the neocortex.

They contribute to action potential repolarization and after-hyperpolarization, which are key for regulating firing frequency and preventing excessive excitability.

2. **Hippocampus:**

In the hippocampus, which is crucial for learning and memory, BK channels are present in neurons of the CA1 and CA3 regions, particularly in the dendrites and soma.

They regulate dendritic calcium spikes and synaptic plasticity, affecting long-term potentiation (LTP) and memory formation processes.

3. **Basal Ganglia:**

BK channels are prominent in the basal ganglia, particularly in striatal medium spiny neurons and dopaminergic neurons of the substantia nigra.

These channels help control motor function by modulating neuronal firing patterns and action potential bursts, which are critical in disorders like Parkinson's disease.

4. **Cerebellum:**

In the cerebellum, BK channels are highly expressed in Purkinje cells, where they regulate the timing and precision of action potentials, essential for motor coordination.

5. **Thalamus:**

BK channels are involved in thalamic relay neurons, controlling burst firing and rhythmic oscillations that are important for sleep-wake cycles and sensory processing.

6. **Brainstem:**

In brainstem regions, particularly those controlling autonomic functions like respiration and heart rate, BK channels regulate neuronal excitability and firing patterns in response to physiological demands.

Pharmacological Properties:

BK channels exhibit unique pharmacological properties due to their sensitivity to both voltage and intracellular calcium levels. Several pharmacological agents, including channel openers and blockers, have been identified and explored for their therapeutic potential.

1. **Calcium and Voltage Dependence:**

BK channels open in response to both membrane depolarization and elevated intracellular calcium. This dual activation mechanism allows precise regulation of neuronal excitability in response to various stimuli.

The gating of BK channels is highly sensitive to changes in calcium concentration, particularly in submicromolar to micromolar ranges, allowing them to respond quickly to calcium influx during synaptic activity or action potentials.

2. **Pharmacological Modulators:**

Channel Openers (Activators): Compounds like NS1619 and NS11021 are well-known BK channel activators. These drugs enhance potassium efflux by increasing the likelihood of channel opening, leading to membrane hyperpolarization and reduced neuronal excitability. Such activators have potential therapeutic applications in conditions characterized by excessive neuronal activity, such as epilepsy and chronic pain.

Channel Blockers: Drugs like iberiotoxin (IbTX) and paxilline are specific BK channel blockers. These agents inhibit BK channel function by binding to the pore region, preventing potassium ion flow. BK channel blockers have been used in research to study the channel's role in various physiological processes, including synaptic transmission and muscle contractility.

Retigabine (Ezogabine): Although primarily a Kv7 (KCNQ) potassium channel opener, retigabine has shown some modulatory effects on BK channels, contributing to its antiepileptic properties. However, its side effects and eventual market withdrawal highlight the complexity of targeting potassium channels therapeutically.

3. **Neuroprotective Properties:**

BK channel openers are being studied for their neuroprotective potential, as they can reduce excitotoxicity by limiting excessive calcium influx and dampening neuronal overactivity. This makes them attractive candidates for the treatment of neurodegenerative diseases such as Alzheimer's disease, stroke, and traumatic brain injury.

4. **Role in Seizure Modulation:**

BK channels help prevent neuronal hyperexcitability, making them a target for anticonvulsant therapies. Modulating BK channels to enhance their activity could help reduce the likelihood of seizures, particularly in cases of drug-resistant epilepsy.

Physiological and Pathological Roles:

Synaptic Transmission: BK channels modulate neurotransmitter release by regulating calcium dynamics and action potential duration in presynaptic terminals. This ensures proper timing of synaptic vesicle release, maintaining efficient communication between neurons.

Neuronal Firing and Rhythmicity: In both excitatory and inhibitory neurons, BK channels play a role in regulating action potential repolarization, after-hyperpolarization, and burst firing. This is critical for maintaining balance in neuronal circuits and preventing pathological overactivity.

Epilepsy: Dysfunctional BK channels have been implicated in some forms of epilepsy. Either an overactivity or underactivity of these channels can contribute to abnormal neuronal firing patterns that lead to seizures. Thus, targeting BK channels pharmacologically represents a promising ave**nue for seizure control.**

Neurodegenerative Disorders: Abnormal BK channel activity has been linked to neurodegenerative diseases, including Parkinson's disease, where improper regulation of firing patterns in dopaminergic neurons can disrupt motor control.

Factors for Choosing an Antiepileptic Drug :

Seizure Type: Some AEDs are more effective for focal seizures, while others work better for generalized seizures.

Side Effects: Different AEDs have different side effect profiles, including drowsiness, dizziness, cognitive impairment, and organ toxicity (e.g., liver).

Comorbidities: Conditions like migraines, mood disorders, and chronic pain may influence the choice of AED.

Age and Gender: Some AEDs may have specific considerations for women of childbearing age due to teratogenic risks, and others may be preferred in pediatric or elderly populations.

Common Side Effects of Antiepileptic Drugs:

Drowsiness, dizziness, fatigue

Cognitive slowing or memory issues

Weight gain or loss

Rash (potentially serious, especially with Lamotrigine)

Liver or kidney toxicity (e.g., Valproate, Phenytoin

With over 20 different antiepileptic drugs available, the choice of medication depends on various factors like seizure type, patient age, comorbidities, and potential side effects.

Conclusions :

BK channels are widely distributed in the CNS, both in the cell body and at the presynaptic

Terminal; the most abundant level of BK channels is found in brain areas largely involved in

Epilepsy, namely cortex, hippocampus, piriform cortex, and other limbic structures. This wide

Distribution emphasizes their contribution in the control of CNS excitability. BK channels are

Responsible for the generation of the fAHP seen immediately after an AP. BK channels

Through the control of AP shape and duration, have an important function in regulating

Membrane excitability and Ca2+ signalling. Physiologically, an increase in K+

Conductance

Might correspond to a reduction in cell excitability; however, BK channels seem to have a

Modulatory effect, which might lead to increased excitability when their function is either Increased or decreased. In agreement,

BK channels have been demonstrated to either inhibit
Or enhance firing frequency in rat hippocampal CA1 pyramidal cells. This ability is directly
Connected to the shape of Aps. Not surprisingly, BK channels are physiologically highly
Modulated by several endogenous modulators. Finally, the role of such channels in the CNS is
Further complicated by their ability to modulate neurotransmitter release.
In theory, under physiological conditions, through a negative feedback mechanism, BK Channels modulate both neuronal membrane potential and intracellular Ca2+ signalling,
Potassium channels, particularly the various subtypes like voltage-gated (Kv), calciumactivated (Kca), and inwardly rectifying potassium (Kir) channels, offer promising potential for the treatment of epileptic diseases. These channels are vital regulators of neuronal excitability, influencing the generation and propagation of action potentials in the brain. Dysfunctions in potassium channels, whether due to genetic mutations or pathological alterations, have been linked to the development of epilepsy, making them attractive therapeutic targets.
Pharmacological modulation of potassium channels, through the use of channel activators or inhibitors, presents a novel therapeutic strategy for managing epilepsy, especially in drug-resistant cases. Compounds like retigabine have shown that enhancing potassium channel activity can reduce seizure frequency, though further research is needed to improve the safety and efficacy of such treatments.

Future advancements in precision medicine, combined with a deeper understanding of potassium channel biology, could lead to the development of more targeted therapies for epilepsy, offering hope for better management of the disease. Ultimately, potassium channels hold significant potential as a transformative approach for treating epileptic diseases and improving patient outcomes.

References

1. *Sah P. Ca(2+)-activated K+ currents in neurones: types, physiological roles and Modulation. Trends Neurosci 1996; 19:150-4.*
2. *Vergara C, Latorre R, Marrion NV, Adelman JP. Calcium-activated potassium Channels. Curr Opin Neurobiol 1998; 8:321-9.*
3. *Martire M, Barrese V, D'Amico M et al. Pre-synaptic BK channels selectively control Glutamate versus GABA release from cortical and hippocampal nerve terminals. J Neurochem 2010; 115:411-22.*
4. *Raffaelli G, Saviane C, Mohajerani MH et al. BK potassium channels control Transmitter release at CA3-CA3 synapses in the rat hippocampus. J Physiol 2004; 557:147-57.*
5. *Jensen BS, Strobaek D, Olesen SP, Christophersen P. The Ca2±activated K+ channel Of intermediate conductance: a molecular target for novel treatments? Curr Drug Targets 2001; 2:401-22.*
6. *Sharman JL, Mpamhanga CP, Spedding M, Germain P, Staels B, Dacquet C, Laudet V, Harmar AJ (2011) IUPHAR-DB: new Receptors and tools for easy searching and visualization of Pharmacological data. Nucleic Acids Res 39:D534–D538*
7. *delman JP, Clapham DE, Hibino H, Inanobe A, Jan LY, Karschin A, Kubo Y, Kurachi Y, Lazdunski M, Miki T, Nichols CG, Pearson WL, Seino S, Vandenberg CA (2011) IUPHAR*
8. *Database (IUPHAR-DB): inwardly rectifying potassium channels*
9. *Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y (2010) Inwardly*

rectifying potassium channels: their structure, Function, and physiological roles. Physiol Rev 90:291–366

10. *Kubo Y, Adelman JP, Clapham DE, Jan LY, Karschin A, Kurachi Y, Lazdunski M, Nichols CG, Seino S, Vandenberg CA (2005)*
11. *International Union of Pharmacology LIV. Nomenclature and Molecular relationships of inwardly rectifying potassium channels. Pharmacol Rev 57:509– 526*
12. *Goldstein SA, Bayliss DA, Kim D, Lesage F, Plant LD, Rajan S (2005) International Union of Pharmacology. LV. Nomenclature And molecular relationships of two-P potassium channels. Pharmacol Rev 57:527–540*
13. *Plant LD, Bayliss DA, Kim D, Lesage F, Goldstein SAN (2012) TwoP potassium channels. IUPHAR database. http://www.iuphar-dp. Org/DATABASE/FamilyMenuForward?familyId=79*
14. *Piechotta PL, Rapedius M, Stansfeld PJ, Bollepalli MK, Erhlich G, Andres-Enguix I, Fritzenschaft H, Decher N, Sansom MS, Tucker SJ, Baukrowitz T (2011) The pore structure and gating Mechanism of K2P channels. EMBO J 30:3607–3619*
15. *Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H (2005) International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium Channels. Pharmacol Rev 57:463–472*
16. *Vacher H, Mohapatra DP, Trimmer JS (2008) Localization and Targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev 88:1407–1447*
17. *Maljevic S, Wuttke TV, Lerche H (2008) Nervous system KV7 Disorders: breakdown of a subthreshold brake. J Physiol 586:1791–1801*